


Fund in focus: Brompton Global Healthcare Income & Growth ETF (HIG & HIG.U)

The newest COVID-19 variant, Omicron, has placed a spotlight on the healthcare sector, particularly vaccine manufacturers and life science companies. Initial reports suggest that this latest strain is spreading at a faster rate than previous ones, including Delta, but it remains to be seen if that has to do with its contagiousness or its ability to escape immunity, whether that immunity was obtained through vaccination or prior infection. While it is too early to conclude the level of efficacy the current line of vaccines has against infection by the Omicron strain, it is highly likely that the existing vaccines will continue to protect against severe outcomes, such as hospitalization and death. Additionally the novel platform for vaccine manufacturing promises to significantly reduce the time for developing a booster that specifically targets new COVID-19 strains. In the early days of the pandemic, COVID-19 revenue was estimated to be lump-sum in nature once vaccinated with a one or two dose regimen (see figure on the left below). Today, estimates for vaccine revenue have increased significantly for year 1 and year 2, which reflect the shift towards frequent booster shots (see figure on the right below). With the propensity of new strains having more mutations, more frequent boosters than originally envisioned could drive more recurring revenue for vaccine manufacturers. As it becomes increasingly likely that COVID-19 could become endemic like the flu, COVID-19 treatments and testing will continue to benefit the pharma, life sciences, and lab companies.

COVID-19 Vaccine Revenue Estimate



Source: Bloomberg (November 30, 2021)

Investors continue to be concerned about inflation, especially since the US Fed Chairman acknowledged that risk of higher inflation has increased. Healthcare is one of the few sectors that has a positive correlation to both rising rates and falling breakeven inflation, and since 1960 the healthcare sector has outperformed the broader market by 3% annualized, according to Goldman Sachs (November 16, 2021). Currently, healthcare represents 16% of 2022 EPS in the S&P 500, however the sector's market cap only represents 13% of the broader index. We believe the gap will narrow over time as share price appreciation generally follows earnings. Big political changes to push down drug prices are unlikely since they have been absent in the latest proposed bills. Overall, we believe the healthcare sector provides investors with an attractive reward/risk opportunity in the current inflationary environment with valuations at multi-decade troughs relative to the broader market and abating political/regulatory risk in the sector.

Brompton's Approach

We believe the healthcare sector plays a defensive role in portfolios while offering solid return potential. [Brompton Global Healthcare Income & Growth ETF \(HIG & HIG.U\)](#) provides significant exposure to the global healthcare sector. In addition, we actively manage the healthcare weighting across our global dividend portfolios (BDIV, GDV, EDGF). Brompton Global Healthcare Income & Growth ETF (HIG & HIG.U) is actively managed and employs a barbell-approach i.e. overweighting subsectors that have structural tailwinds and underweighting subsectors with near-term overhangs. We also use an actively managed call writing overlay to harvest volatility risk premium which enhances risk-adjusted returns

This document is for information purposes only and does not constitute an offer to sell or a solicitation to buy the securities referred to herein. The opinions contained in this report are solely those of Brompton Funds Limited ("BFL") and are subject to change without notice. BFL makes every effort to ensure that the information has been derived from sources believed to be reliable and accurate. However, BFL assumes no responsibility for any losses or damages, whether direct or indirect which arise from the use of this information. BFL is under no obligation to update the information contained herein. The information should not be regarded as a substitute for the exercise of your own judgment. Please read the prospectus before investing.

Commissions, trailing commissions, management fees and expenses all may be associated with exchange-traded fund investments. Please read the prospectus before investing. Exchange-traded funds are not guaranteed, their values change frequently and past performance may not be repeated.

Certain statements contained in this document constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to matters disclosed in this document and to other matters identified in public filings relating to the Fund, to the future outlook of the Fund and anticipated events or results and may include statements regarding the future financial performance of the Fund. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "intend", "estimate", "predict", "potential", "continue" or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Investors should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and we assume no obligation to update or revise them to reflect new events or circumstances.



VALUE
INTEGRITY
PERFORMANCE
THE FOUNDATION FOR EXCELLENCE

Investor Relations

PHONE 416.642.6000
TOLL FREE 1.866.642.6001
FAX 416.642.6001
EMAIL info@bromptongroup.com

Website

www.bromptongroup.com

Address

Bay Wellington Tower,
Brookfield Place
181 Bay Street
Suite 2930, Box 793
Toronto, Ontario M5J 2T3